

## Ligand Pharmaceuticals

[View the current Ligand Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/6481-Ligand+Pharmaceuticals.html)

(<http://www.bioportfolio.com/biocorporate/6481-Ligand+Pharmaceuticals.html>)

### Contact Details:

**10275 Science Center Drive**  
**San Diego**  
**CA**  
**92121-1117**  
**United States of America**

Tel: 858 550 7500  
Fax: 858 550 7506  
Email: [investors@ligand.com](mailto:investors@ligand.com)

Ligand is an emerging specialty pharmaceutical company that discovers, develops and markets innovative small molecule drugs to address critical, unmet medical needs. Ligand markets four oncology and dermatology products in the United States – ONTAK®, Targretin® capsules, Targretin® gel and Panretin® gel. Ligand launched its fifth product, AVINZA™, a treatment for chronic, moderate-to-severe pain, in the second quarter of this year. In addition, Ligand's network of major pharmaceutical partners is developing products for men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's robust R&D pipeline is based on the company's leadership in gene transcription technology.

### Recent Publications by Ligand Pharmaceuticals:



- [2-Benzimidazolyl-9-\(chroman-4-yl\)-purinone derivatives as JAK3 inhibitors.](#)  
*A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a...*20th October, 2009  
Ligand Pharmaceuticals,- Bioorg Med Chem Lett. 2009 Dec 1;19(23):6788-92. Epub 2009 Sep 25. ([DOI Direct Link](#))
- [Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.](#)  
*The profile of a series of triazine and pyrimidine based ROCK inhibitors...*6th October, 2009  
Ligand Pharmaceuticals, Inc., 3000 Eastpark Boulevard, Cranbury, NJ 08512,- Bioorg Med Chem Lett. 2009 Nov 1;19(21):6027-31. Epub 2009 Sep 17. ([DOI Direct Link](#))
- [Combination treatment with a selective androgen receptor modulator q\(SARM\) and a bisphosphonate has additive effects in osteopenic female rats.](#)  
*Recent clinical trials with bisphosphonates and PTH have not supported the...*29th August, 2009  
Discovery Research, Ligand Pharmaceuticals, San Diego, California 92121,- J Bone Miner Res. 2009 Feb;24(2):231-40. ([DOI Direct Link](#))

- [Novel CXCR3 antagonists with a piperazinyl-piperidine core.](#)  
*High-throughput screening of an encoded combinatorial aryl piperazine...* 4th August, 2009  
Ligand Pharmaceuticals, 3000 Eastpark Boulevard, Cranbury, NJ 08512, USA.- *Bioorg Med Chem Lett.* 2009 Sep 1;19(17):5205-8. Epub 2009 Jul 9. ([DOI Direct Link](#))
- [Pharmacokinetics and pharmacodynamics of LGD-3303 \[9-chloro-2-ethyl-1-methyl-3-\(2,2,2-trifluoroethyl\)-3H-pyrrolo-\[3,2-f\]quinolin-7\(6H\)-one\], an orally available nonsteroidal-selective androgen receptor modulator.](#)  
*Selective androgen receptor modulators (SARMs) are a new class of...* 24th February, 2009  
Discovery Research, Ligand Pharmaceuticals, Inc., San Diego, California,- *J Pharmacol Exp Ther.* 2009 Feb;328(2):663-70. Epub 2008 Nov 18. ([DOI Direct Link](#))
- [Discovery of nonsteroidal glucocorticoid receptor ligands based on 6-indole-1,2,3,4-tetrahydroquinolines.](#)  
*A series of nonsteroidal glucocorticoid receptor (GR) ligands based on a...* 30th August, 2008  
Discovery Research, Ligand Pharmaceuticals, 10275 Science Center Drive,- *Bioorg Med Chem Lett.* 2008 Jun 15;18(12):3504-8. Epub 2008 May 11. ([DOI Direct Link](#))
- [A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-\(3-methylcyclohex-2-enyl\)-2,2,4-trimethyl-1,2-dihydrochrome no\[3,4-f\]quinoline.](#)  
*The progesterone receptor plays an important role in the female...* 13th August, 2008  
Discovery Research, Ligand Pharmaceuticals Inc., 10275 Science Center- *J Med Chem.* 2008 Jul 10;51(13):3696-9. Epub 2008 Jun 14. ([DOI Direct Link](#))
- [Discovery of structurally diverse nonsteroidal SPRMs based on a screening hit, 1,2-dihydro-2,2,4-trimethyl-6-phenylquinolinone.](#)  
*Synthetic steroidal progestins and antiprogestins have been widely used...* 25th July, 2008  
Discovery Research, Ligand Pharmaceuticals Inc., 10275 Science Center- *Curr Top Med Chem.* 2008;8(9):766-80.
- [Recent developments in the discovery of selective glucocorticoid receptor modulators \(SGRMs\).](#)  
*Steroidal glucocorticoids are widely prescribed for the treatment of a...* 25th July, 2008  
Discovery Research, Ligand Pharmaceuticals, 10275 Science Center Drive,- *Curr Top Med Chem.* 2008;8(9):750-65.
- [Selective androgen receptor modulators based on a series of 7H-\[1,4\]oxazino\[3,2-g\]quinolin-7-ones with improved in vivo activity.](#)  
*Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the...* 17th July, 2008  
Discovery Research, Ligand Pharmaceuticals, 10275 Science Center Drive,- *Bioorg Med Chem Lett.* 2008 May 1;18(9):2967-71. Epub 2008 Mar 23. ([DOI Direct Link](#))
- [Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.](#)  
*A novel oxachrysenone series (2) of nonsteroidal selective androgen...* 10th July, 2008  
Discovery Research, Ligand Pharmaceuticals Inc., 10275 Science Center- *Bioorg Med Chem Lett.* 2008 Jun 1;18(11):3431-5. Epub 2008 Apr 8. ([DOI Direct Link](#))
- [LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo.](#)  
*Treatment of inflammation is often accomplished through the use of...* 11th June, 2008  
Discovery Research, Ligand Pharmaceuticals, San Diego, California 92121,- *Endocrinology.* 2008 May;149(5):2080-9. Epub 2008 Jan 24. ([DOI Direct Link](#))
- [Cell-specific activation of the human skeletal alpha-actin by androgens.](#)  
*Although it is evident that androgens increase muscle mass and strength,...* 23rd April, 2008  
Department of Research and Development, Ligand Pharmaceuticals Inc., 10275- *Endocrinology.* 2008 Mar;149(3):1103-12. Epub 2007 Dec 6. ([DOI Direct Link](#))
- [Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.](#)  
*Glucocorticoids are commonly used antiinflammatory agents whose use is...* 19th January, 2008  
Discovery Research, Ligand Pharmaceuticals, San Diego, CA 92121, USA.- *Proc Natl Acad Sci U S A.* 2007 Dec 4;104(49):19244-9. Epub 2007 Nov 21. ([DOI Direct Link](#))
- [Substituted 6-\(1-pyrrolidine\)quinolin-2\(1H\)-ones as novel selective androgen receptor modulators.](#)  
*The androgen receptor is a ligand inducible transcription factor that is...* 6th December, 2007

**Press Releases on Ligand Pharmaceuticals:**

|  |                            |                                     |   |
|--|----------------------------|-------------------------------------|---|
| <p><a href="#">Reportlinker Adds Imaging Agents - A Worldwide Market Review</a></p>  | <p>20th November, 2009</p> | <p>Reportlinker</p>                 | <p>NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Imaging Agents - A Worldwide Market Review <a href="http://www.reportlinker.com">http://www.reportlinker.com</a></p> |
| <p><a href="#">AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured</a></p> | <p>20th November, 2009</p> | <p>AstraZeneca</p>                  | <p>WILMINGTON, Del., Nov. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and the Philadelphia Department of Public Health announced today at a press conference at Philadelphia Health Care Center #6</p>                                       |
| <p><a href="#">Impax Laboratories Drives Stronger Performance with IBM Business Analytics</a></p>                                      | <p>20th November, 2009</p> | <p>IBM</p>                          | <p>-- C-level Executive Committee can now easily pull together a single view of net sales, profitability and competitive market share information, helping them to determine whether</p>  |
| <p><a href="#">Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference</a></p>                       | <p>19th November, 2009</p> | <p>Alexza Pharmaceuticals, Inc.</p> | <p>MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate presentation will be webcast live during the 21st Annual Piper</p>   |
| <p><a href="#">AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season</a></p>       | <p>19th November, 2009</p> | <p>Medialink</p>                    | <p>NEW YORK, Nov. 19 /PRNewswire/ -- As the seasons change, another season of coughs and running noses is here. Here's more on preparing yourself. Listen to this report from Ortho-McNeil-Janssen</p>  |

**BioNews Results for Ligand Pharmaceuticals**



- [arGentis Acquires Rights to Rheumatoid Arthritis Therapy Entering Phase I Clinical Trial](#)  
*PipelineReview: Nov 14 2009 9:32PM Matching: ligand pharmaceuticals*
- [arGentis Acquires Rights to Rheumatoid Arthritis Therapy Entering Phase I Clinical Trial](#)  
*Pharmacy Choice: Nov 12 2009 10:12PM Matching: ligand pharmaceuticals*
- [Into the Hot Seat](#)  
*GenomeWeb: Nov 12 2009 6:20PM Matching: ligand pharmaceuticals*
- [arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand](#)  
*News-Medical.Net: Nov 12 2009 3:27PM Matching: ligand pharmaceuticals*
- [Sequenom Looks to Prolong Operations as Available Cash Runs Low](#)  
*Xconomy: Nov 11 2009 1:33AM Matching: ligand pharmaceuticals*
- [Sanofi-Aventis Commits Over \\$2.8B to Regeneron in mAb Discovery Alliance](#)  
*Genetic Engineering News: Nov 11 2009 6:04PM Matching: ligand pharmaceuticals*
- [BRIEF: Pfizer, Ligand ink JAK-3 pact](#)  
*TradingMarkets: Nov 10 2009 7:58AM Matching: ligand pharmaceuticals*
- [Pfizer extends Ligand research collaboration](#)  
*Individual.com: Nov 10 2009 12:09PM Matching: ligand pharmaceuticals*
- [BRIEF: Pfizer, Ligand ink JAK-3 pact](#)  
*Individual.com: Nov 10 2009 1:02PM Matching: ligand pharmaceuticals*
- [Pfizer extends Ligand research collaboration](#)  
*TradingMarkets: Nov 9 2009 5:18PM Matching: ligand pharmaceuticals*
- [Hormones: New hormones study findings have been reported by scientists at GlaxoSmithKline](#)  
*NewsRX: Nov 9 2009 5:55AM Matching: ligand pharmaceuticals*
- [Ligand's JAK3 Research Collaboration Extended by Pfizer](#)  
*PipelineReview: Nov 8 2009 9:05PM Matching: ligand pharmaceuticals*
- [Ligand's JAK3 Research Collaboration Extended by Pfizer](#)  
*PipelineReview: Nov 8 2009 9:05PM Matching: ligand pharmaceuticals*
- [Pfizer extends JAK3 research collaboration with Ligand](#)  
*PharmaBiz: Nov 7 2009 9:45AM Matching: ligand pharmaceuticals*
- [Vivakor, Inc. & Ligand Pharmaceuticals Incorporated](#)  
*Pharmacy Choice: Nov 7 2009 2:38AM Matching: ligand pharmaceuticals*

#### Ligand Pharmaceuticals Clinical Trials:



- [A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma](#)

#### Ligand Pharmaceuticals Patents:



- 6462038- [Androgen receptor modulator compounds and methods](#)
- 6593493- [RXR modulators with improved pharmacologic profile](#)
- 6608068- [Indoline derivatives](#)
- 6610696- [Modulators of peroxisome proliferator activated receptors](#)
- 6610883- [Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors](#)
- 6667313- [8-substituted-6-trifluoromethyl-9-pyrido \[3,2-G\] quinoline compounds as androgen receptor modulators](#)
- 6670387- [Thrombopoietin mimetics](#)
- 6693103- [1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives as progesterone receptor modulators](#)
- 6696459- [Steroid receptor modulator compounds and methods](#)
- 6713478- [Cyclocarbamate derivatives as progesterone receptor modulators](#)
- 6759408- [Combination regimens using progesterone receptor modulators](#)
- 6583145- [Thio-oxindole derivatives](#)
- 6576676- [Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor](#)
- 6566372- [Bicyclic androgen and progesterone receptor modulator compounds and methods](#)
- 6498154- [Cyclic regimens using quinazolinone and benzoxazine derivatives](#)
- 6503939- [Combination regimens using 3,3-substituted indoline derivatives](#)
- 6506766- [Glucocorticoid-selective antiinflammatory agents](#)
- 6509334- [Cyclocarbamate derivatives as progesterone receptor modulators](#)
- 6521633- [Treating NIDDM with RXR agonists](#)
- 6521657- [Thio-oxindole derivatives](#)
- 6534516- [Androgen receptor modulator compounds and methods](#)
- 6544970- [Cyclic regimens utilizing indoline derivatives](#)
- 6545049- [Dimer-selective RXR modulators and methods for their use](#)
- 6566358- [Cyclocarbamate derivatives as progesterone receptor modulators](#)
- 6794373- [Contraceptive methods using benzimidazolones](#)
- 6825222- [Modulators of peroxisome proliferator activated receptors](#)
- 7084151- [5-\(1',1'-cycloalkyl/alkenyl\)methylidene 1,2-dihydro-5H-chromeno\[3,4-f\]quinolines as selective progesterone receptor modulator compounds](#)
- 7098025- [Human peroxisome proliferator activated receptor gamma \(ppar.gamma.\) gene regulatory sequences and uses therefor](#)
- 7098310- [Heterodimers of retinoid X receptors \(RXRS\) and other steroid hormone receptors](#)
- 7163946- [5-substituted 7,9-difluoro-5H-chromeno\[3,4-f\]quinoline compounds as selective progesterone receptor modulator compounds](#)
- 7192982- [Modulators of peroxisome proliferator activated receptors](#)
- 7214690- [Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods](#)
- 7314887- [Thrombopoietin activity modulating compounds and methods](#)
- 7348359- [Retinoid X receptor modulators](#)
- 7435733- [Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds](#)
- 7439027- [Method for modulating process mediated by farnesoid activated receptors](#)
- 7081457- [Cyclothiocarbamate derivatives as progesterone receptor modulators](#)
- 7071205- [5-cycloalkenyl 5H-chromeno\[3,4-f\]quinoline derivatives as selective progesterone receptor modulator compounds](#)
- 7056954- [Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor](#)
- 6835744- [3,3-substituted indoline derivatives](#)
- 6841568- [Thio-oxindole derivatives](#)
- 6946454- [Thio-oxindole derivatives](#)

- 6951942- [Glucocorticoid-selective anti-inflammatory agents](#)
- 6964973- [Bicyclic androgen and progesterone receptor modulator compounds and methods](#)
- 6982261- [Cyanopyrroles](#)
- 6992108- [Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor](#)
- 7026125- [Heterodimers of retinoid X receptors \(RXRS\) and other steroid hormone receptors](#)
- 7026484- [Tricyclic androgen receptor modulator compounds and methods](#)
- 7041498- [Method for modulating processes mediated by farnesoid activated receptors](#)
- 7442696- [Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:Peter.Barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

